Article Text

Download PDFPDF

SAT0244 A long-term follow-up study of allogeneic mesenchymal stem cells transplantation in patients with drug-resistant systemic lupus erythematosus
  1. D Wang1,
  2. L Sun2
  1. 1Department of Rheumatology and Immunology
  2. 2Department of Rheumatology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China


Background Allogeneic mesenchymal stem cells (MSC) transplantation showed therapeutic effect in active and refractory systemic lupus erythematosus (SLE).

Objectives To determine the long-term safety and efficacy of allogeneic MSC transplantation (allo-MSCT) in severe SLE patients refractory to previous therapies.

Methods All consecutive SLE patients who received at least one allo-MSCT were analyzed. SLEDAI score of more than or equal to 8 or with at least one BILAG grade A or at least two BILAG grade B manifestations. All the patients were refractory to corticosteroid and/or immunosuppressive drugs treatment. Allogeneic bone marrow and/or umbilical cord derived MSCs were infused intravenously, with one million cells per kilogram of bodyweight for each infusion. The primary end point was 5-year overall survival. Secondary end points included complete clinical remission, partial clinical remission and relapse.

Results Eighty-one patients were enrolled and underwent allo-MSCT. Thirteen patients died within 5 years post-MSCT and the 5-year overall survival rate was 84% (68/81). At 5-year follow-up, 22 patients (22/68, 32%) were in complete clinical remission and another 6 patients (6/68, 9%) were in partial clinical remission, and the 5-year disease remission was 41% (28/68). In total, 37 patients had achieved clinical remission (27 in complete remission and 10 in partial remission) at the 5 years visit and then 9 patients subsequently relapsed. The 5-year overall rate of relapse was 24% (9/37). SLEDAI scores, levels of serum albumin and complement C3, peripheral white blood cell and platelet numbers, as well as proteinuria levels continued to improve during the follow-up.

Conclusions Allogeneic MSCT is safe and resulted in long-term clinical remission in severe and drug-resistant SLE patients.

Disclosure of Interest None declared

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.